Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer

Figures & data

Table 1 Effect of HX-1162 on cancer cell viability

	24 hours		48 hours
	Control	HX-1162	Control	HX-1162
Viable cells, % ± SD	99.8% ± 0.1%	27.0% ± 9.4%	99.7% ± 0.03%	18.6% ± 7.8%

Abbreviation: SD, standard deviation.

Figure 1 Effect of HX-1162 on cancer cell apoptosis in vitro.

Note: Longer HX-1162 treatment increased the cancer cell apoptosis in vitro.

Figure 2 Effect of HX-1162 on tumor growth in vivo.

Note: At different time points, the in vivo administration of HX-1162 slowed down the tumor growth after graft, in a dose-dependent manner.

Table 2 HX-1162-induced cancer cell apoptosis in vivo (30 days)

	Saline	HX-1162, 10 mg/kg	HX-1162, 20 mg/kg
Apoptotic cells, % ± SD	1.7% ± 0.3%	29.5% ± 7.4%	36.4% ± 8.9%

Abbreviation: SD, standard deviation.